Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Aimmune Therapeutics, Inc.    AIMT

AIMMUNE THERAPEUTICS, INC.

(AIMT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Aimmune Therapeutics, Inc. is a biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens. PALFORZIA is its internally developed product utilizing CODIT. PALFORZIA is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that occurs with accidental exposure to peanut. PALFORZIA is to be used in conjunction with a peanut-avoidant diet. Its subsidiaries include Aimmune Therapeutics UK Limited, Aimmune Therapeutics (Bermuda) Ltd., Aimmune Therapeutics Netherlands Cooperatief U.A., Aimmune Therapeutics Netherlands B.V., Aimmune Therapeutics Ireland Limited and Aimmune Therapeutics Germany GmbH.

Number of employees : 275 people.
Managers
NameAgeSinceTitle
Jayson Donald Alexander Dallas, Dr.512018President, Chief Executive Officer & Director
Mark D. McDade632015Chairman
Eric Hands Claude Bjerkholt592017Chief Financial Officer
Daniel C. Adelman, Dr.612016Chief Medical Officer
Narinder Singh-2020Executive Vice President-Technical Operations
Patrick G. Enright572013Independent Non-Employee Director
Stacey Denenberg Seltzer422015Independent Director
Kathryn E. Falberg582015Independent Director
Mark Iwicki522015Independent Director
Grégory Behar492016Independent Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 65,450,142 50,930,993 77.8% 0 0.0% 77.8%
Shareholders
NameEquities%
T. Rowe Price Associates, Inc. (Investment Management) 5,274,902 8.06%
The Vanguard Group, Inc. 4,066,312 6.21%
Palo Alto Investors LP 3,318,212 5.07%
Eventide Asset Management LLC 3,193,117 4.88%
Foresite Capital Management LLC 2,605,499 3.98%
Fidelity Management & Research Co. LLC 2,218,709 3.39%
Goldman Sachs & Co. LLC (Private Banking) 2,179,603 3.33%
Alpine Associates Management, Inc. 2,075,100 3.17%
SSgA Funds Management, Inc. 2,044,893 3.12%
Fiera Capital Corp. (Investment Management) 1,575,531 2.41%
Company contact information
Aimmune Therapeutics, Inc.
8000 Marina Boulevard
Suite 300
Brisbane, CA 94005-1884

Phone : +1.650.614.5220
Fax : +1.650.616.0075
Web : http://www.aimmune.com
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
AIMMUNE THERAPEUTICS, INC.3.05%2 268
GILEAD SCIENCES, INC.-8.43%74 585
VERTEX PHARMACEUTICALS-0.39%56 714
REGENERON PHARMACEUTICALS35.38%53 649
WUXI APPTEC CO., LTD.55.32%37 691
BIONTECH SE209.80%25 273
BEIGENE, LTD.59.36%24 079
GENMAB A/S52.01%23 574
ARGENX SE55.01%12 550
MYOKARDIA, INC.208.58%11 993
HUALAN BIOLOGICAL ENGINEERING INC.52.60%11 448
MIRATI THERAPEUTICS, INC.74.97%11 336
SAREPTA THERAPEUTICS, INC.5.18%10 710
NEUROCRINE BIOSCIENCES, INC.-10.87%8 887
ASCENDIS PHARMA A/S16.55%8 661
ULTRAGENYX PHARMACEUTICAL INC.180.57%7 927
DENALI THERAPEUTICS INC.247.99%7 269
ACCELERON PHARMA INC.114.54%6 854
BIOCON LIMITED43.05%6 749
KODIAK SCIENCES INC.83.74%6 659
PEPTIDREAM INC.-10.54%6 034